Literature DB >> 1530980

Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation.

C Pique1, D Pham, T Tursz, M C Dokhélar.   

Abstract

The human T-cell leukemia virus type I (HTLV-I) envelope protein is synthesized as a gp61 precursor product cleaved into two mature proteins, a gp45 exterior protein and a gp20 anchoring the envelope at the cell membrane. Using N-glycosylation inhibitors and site-directed mutagenesis of the potential glycosylation sites, we have studied the HTLV-I envelope intracellular maturation requirements for syncytium formation. We show here that experimental conditions resulting in the absence of precursor cleavage (tunicamycin, monensin treatments, and use of inhibitors of the reticulum steps of the N glycosylations) also result in no cell surface expression of envelope protein. The lack of syncytium formation observed in these cases is thus explained by incorrect intracellular transport. When the precursor is cleaved in the Golgi stack (no treatment or treatment with inhibitors of the Golgi steps of the N glycosylations), it is transported to the cell surface in all the cases examined. Syncytium formation is markedly reduced, however, when Golgi glycosylations are incorrect, which shows that the sugar moieties are involved in the envelope functions. Site-directed mutagenesis demonstrates that each of the five potential glycosylation sites is actually glycosylated. Glycosylation of sites 1 and 5 is required for normal maturation, whereas that of sites 2, 3, and 4 is dispensable. Glycosylation of each site, however, is required for normal syncytium formation. Altogether, the restraints exerted by the cell for the HTLV-I envelope to be transported and functional are very high, which might play a role in the observed conservation of the envelope amino acid sequence between various strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530980      PMCID: PMC240791     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Envelope gene sequence of HTLV-1 isolate MT-2 and its comparison with other HTLV-1 isolates.

Authors:  G S Gray; M White; T Bartman; D Mann
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

Review 2.  Perturbation of vesicular traffic with the carboxylic ionophore monensin.

Authors:  A M Tartakoff
Journal:  Cell       Date:  1983-04       Impact factor: 41.582

3.  Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of Golgi mannosidase II.

Authors:  D R Tulsiani; T M Harris; O Touster
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

4.  HTLV-1 envelope sequences from Brazil, the Caribbean, and Romania: clustering of sequences according to geographic origin and variability in an antibody epitope.

Authors:  T F Schulz; M L Calabrò; J G Hoad; C V Carrington; E Matutes; D Catovsky; R A Weiss
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

5.  Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients.

Authors:  E Paine; J Garcia; T C Philpott; G Shaw; L Ratner
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

6.  Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  R Pal; G M Hoke; M G Sarngadharan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Demonstration of the absence of infectious Rous virus in rat tumour XC, whose structurally intact cells produce Rous sarcoma when transferred to chicks.

Authors:  J SVOBODA; P CHYLE; D SIMKOVIC; I HILGERT
Journal:  Folia Biol (Praha)       Date:  1963-04       Impact factor: 0.906

8.  Sequence variants of human T-cell lymphotropic virus type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates.

Authors:  S Daenke; S Nightingale; J K Cruickshank; C R Bangham
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

9.  Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.

Authors:  M Seiki; S Hattori; Y Hirayama; M Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

10.  Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation?

Authors:  C Pique; T Tursz; M C Dokhelar
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  42 in total

1.  Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.

Authors:  B Kobe; R J Center; B E Kemp; P Poumbourios
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

2.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

5.  Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.

Authors:  David Ghez; Yves Lepelletier; Sophie Lambert; Jean-Marie Fourneau; Vincent Blot; Sébastien Janvier; Bertrand Arnulf; Peter M van Endert; Nikolaus Heveker; Claudine Pique; Olivier Hermine
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion.

Authors:  Michael Wallin; Maria Ekström; Henrik Garoff
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

8.  Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein.

Authors:  L Delamarre; C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Authors:  Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski; Sébastien Janvier; Nikolaus Heveker; Francis W Ruscetti; Gérard Perret; Kathryn S Jones; Claudine Pique
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

10.  Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.

Authors:  Kazu Okuma; Kevin P Dalton; Linda Buonocore; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.